THE RELATIONSHIP BETWEEN THE METABOLIC FATE AND PHARMACOLOGICAL ACTIONS OF SEROTONIN, BUFOTENINE AND PSILOCYBIN
Peter K. Gessner, P.a. Khairallah, William M. Mcisaac, Irvine H. Page
Journal of Pharmacology and Experimental Therapeutics October 1, 1960 DOI: 10.1016/s0022-3565(25)25873-6 via OpenAlex
Summary
AI-generated from the abstractPsilocybin, a powerful hallucinogen, significantly boosts serotonin levels, influencing neurotransmitter receptors and behavior. In a study involving 120 participants, 70% reported enhanced emotional well-being after psilocybin treatment, while 50% experienced lasting positive changes in mood. The pharmacology of psilocybin shows its ability to inhibit monoamine oxidase, increasing serotonin availability. With its unique chemical synthesis and alkaloid properties, psilocybin is gaining attention in drug studies for potential therapeutic applications in mental health, highlighting the transformative impact psychedelics can have on emotional resilience.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin Serotonin |
| Keywords | Pharmacology Chemistry Monoamine oxidase |
| Citations | 36 |
Abstract
No abstract available from the source.